Literature DB >> 7923116

The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia.

C E Canman1, A C Wolff, C Y Chen, A J Fornace, M B Kastan.   

Abstract

The p53 protein is a critical participant in a signal transduction pathway which mediates a G1 cell cycle arrest and apoptotic cell death in mammalian cells after ionizing irradiation. Cells from patients with the cancer-prone, radiation-sensitive disorder, ataxia-telangiectasia (AT), exhibit suboptimal (delayed and/or defective) induction of p53 protein after ionizing radiation with some dependence on dose. Other protein products which participate in this signal transduction pathway, including p21WAF1/CIP1, Gadd45, and Mdm2, are also suboptimally induced in AT cells after ionizing radiation. Induction of p53 is also abnormal in AT cells following treatment with methylmethanesulfonate and bleomycin but appears relatively normal following treatment with UV-C irradiation or the topoisomerase inhibitors, etoposide and camptothecin. These results demonstrate a specific defect in this p53-dependent signal transduction pathway in AT cells. Potential models for this observed specificity of the AT defect as measured by p53 induction include problems with responses to: (a) single-strand, but not double-strand, DNA breaks; or (b) chemically, but not enzymatically, generated DNA ends.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923116

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  56 in total

1.  Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage.

Authors:  N H Chehab; A Malikzay; E S Stavridi; T D Halazonetis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  Spontaneous and oxidative stress-induced programmed cell death in lymphocytes from patients with ataxia telangiectasia (AT).

Authors:  R Schubert; J Reichenbach; N Royer; M Pichler; S Zielen
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

3.  Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage.

Authors:  K Webley; J A Bond; C J Jones; J P Blaydes; A Craig; T Hupp; D Wynford-Thomas
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

4.  ATM protein synthesis patterns in sporadic breast cancer.

Authors:  R Kairouz; R A Clarke; P J Marr; D Watters; M F Lavin; J H Kearsley; C S Lee
Journal:  Mol Pathol       Date:  1999-10

5.  Requirement of ATM in phosphorylation of the human p53 protein at serine 15 following DNA double-strand breaks.

Authors:  K Nakagawa; Y Taya; K Tamai; M Yamaizumi
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

6.  Activation of p53 protein by telomeric (TTAGGG)n repeats.

Authors:  M Milyavsky; A Mimran; S Senderovich; I Zurer; N Erez; I Shats; N Goldfinger; I Cohen; V Rotter
Journal:  Nucleic Acids Res       Date:  2001-12-15       Impact factor: 16.971

7.  Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation.

Authors:  B Xu; M B Kastan
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

8.  Isolation of full-length ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype.

Authors:  N Zhang; P Chen; K K Khanna; S Scott; M Gatei; S Kozlov; D Watters; K Spring; T Yen; M F Lavin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

9.  A variant of the Nijmegen breakage syndrome with unusual cytogenetic features and intermediate cellular radiosensitivity.

Authors:  R Tupler; G L Marseglia; M Stefanini; E Prosperi; L Chessa; T Nardo; A Marchi; P Maraschio
Journal:  J Med Genet       Date:  1997-03       Impact factor: 6.318

10.  Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway.

Authors:  Risa Kitagawa; Christopher J Bakkenist; Peter J McKinnon; Michael B Kastan
Journal:  Genes Dev       Date:  2004-06-02       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.